Medium-term effects of COVID-19 pandemic on epilepsy: A follow-up study

Sofía Lallana1 | Elena Fonseca2,3 | Juan Luis Restrepo1 | Manuel Quintana2,3 | Iván Seijo-Raposo2,3 | Laura Abraira2,3 | Estevo Santamarina2,3 | José Álvarez-Sabin1 | Manuel Toledo2,3

1Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain
2Epilepsy Unit, Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain
3Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain

Correspondence
Elena Fonseca, Epilepsy Unit, Neurology Department, Vall d’Hebron University Hospital, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain.
Email: e.fonseca@vhebron.net

Abstract
Objective: To analyze the medium-term impact of the COVID-19 pandemic on epilepsy patients, focusing on psychological effects and seizure control.
Methods: Prospective follow-up study to evaluate the medium-term effects of the COVID-19 pandemic on a cohort of epilepsy patients from a tertiary hospital previously surveyed during the first peak of the pandemic. Between July 1, 2020, and August 30, 2020, the patients answered an online 19-item questionnaire, HADS, and PSIQ scales. Short- and medium-term effects of the pandemic confinement and the perception of telemedicine were compared.
Results: 153 patients completed the questionnaire, mean ± SD age, 47.6 ± 19.3 years; 49.7% women. Depression was reported by 43 patients, significantly more prevalent than in the short-term analysis (29.2% vs. 19.7%; p = .038). Anxiety (38.1% vs. 36.1%; p = 0.749) and insomnia (28.9% vs. 30.9%, p = .761) remained highly prevalent. Seventeen patients reported an increase in seizure frequency (11.1% vs. 9.1%, p = .515). The three factors independently associated with an increase in seizure frequency in the medium term were drug-resistant epilepsy (odds ratio [OR] = 8.2, 95% CI 2.06–32.52), depression (OR = 6.46, 95% CI 1.80–23.11), and a reduction in income (OR = 5.47, 95% CI 1.51–19.88). A higher proportion of patients found telemedicine unsatisfactory (11.2% vs. 2.4%), and a lower percentage (44.8% vs. 56.8%) found it very satisfactory (p = .005).
Conclusions: Depression rates increased significantly after the first wave. Depression, drug-resistant epilepsy, and a reduction in family income were independent risk factors for an increased seizure frequency. Perception of telemedicine worsened, indicating need for re-adaptation.

KEYWORDS
COVID-19, depression, epilepsy, pandemic, SARS-CoV-2, Seizures, telehealth
INTRODUCTION

Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 2 million deaths worldwide since the first cases were reported in December 2019.1,2 This pandemic has presented the medical community and society with unprecedented challenges.

To control the spread of the COVID-19 pandemic in Spain, the government imposed a nationwide lockdown that lasted from March 13, 2020, to June 20, 2020. After this period, restrictions were gradually eased, giving way to a "new normal" characterized by curtailment of a wide range of everyday activities and new social distancing measures.3 In August 2020, the cumulative 7-day incidence of COVID-19 in Spain was 78.2 cases per 100,000 inhabitants, with nearly 400,000 total cases and 30,000 deaths.4 The healthcare system was struggling to adapt to the new situation, while preparing for a probable second wave.

The collapse of the emergency services in March and April 2020 had a major effect on urgent medical conditions such as heart attacks and stroke, causing treatment delays and increased morbidity and mortality rates.5 Once a certain normalcy had been restored, studies on the medical and psychological effects of lockdown on patients with chronic illnesses began to emerge.6,7

The medical community has made enormous efforts to enable and promote the use of telemedicine as a safe way of monitoring patients with stable illness,8 including those with chronic epilepsy, for whom an array of suitable new technologies exists.9,10 Although telemedicine still has a long way to go, it will certainly provide an essential alternative to traditional in-person visits for some time, and efforts must be made to ensure continued quality of care. Tertiary hospitals in Spain have adapted care protocols and procedures in many areas and prioritized the use of remote monitoring for patients with chronic disease.11

Spanish studies of the impact of the pandemic and lockdown measures in the setting of epilepsy have mainly identified collateral effects,12,13 although one recent study described a higher incidence of COVID-19 in patients with epilepsy than in those without, probably because of the higher proportion of dependent and institutionalized patients in this population.14 A previous cross-sectional survey-based study by our group analyzing the short-term effects of the COVID-19 pandemic on epilepsy patients from a tertiary hospital in Barcelona, Spain, showed emerging lockdown-related symptoms such as anxiety and depression in addition to sleep disturbances and reduced family income.15 Almost 30% of the patients reported an increase in seizure frequency, found to be independently associated with tumor-related epilepsy, drug-resistant epilepsy, insomnia, and reduced income. The general perception of telemedicine among the patients surveyed was positive.

In this follow-up study, we analyzed the medium-term effects of the COVID-19 pandemic in the same cohort of patients,15 with a focus on the psychological impact of the pandemic and lockdown and their possible association with seizure control. We also re-evaluated perceptions of telemedicine, which has since been incorporated into routine practice at our epilepsy unit.

MATERIALS AND METHODS

Study design and participants

In a previous study, we evaluated the short-term effects of the COVID-19 pandemic in a cross-sectional survey of all patients from the epilepsy unit at Hospital Vall d’Hebron in Barcelona, Spain, who had received a telephone consultation during the first month of lockdown (March 16, 2020, to April 17, 2020). Their in-person appointment had been canceled following the Spanish Government’s declaration of a national state of emergency on March 14.16 The full details of the study are described elsewhere.15 In brief, patients aged 17 years or older with a definitive diagnosis of epilepsy according to the International League Against Epilepsy (ILAE) criteria17 were consecutively included. Patients consulting for neurological symptoms other than seizure and patients/caregivers unable to answer the questionnaire were excluded. All epilepsies were classified according to the current ILAE classification.18 Information on antiepileptic drug (AED) treatment, mean baseline seizure frequency, and drug resistance was obtained from medical records. A note was also made of modified Rankin scale score, intellectual disability, dysphagia, and demographic data, including current living and employment situation. All the consultations were performed by an epileptologist by telephone. The patients or their caregivers were then administered a 19-item telephone survey by a neurologist.

The follow-up study to assess the medium-term effects of the pandemic on the same cohort of patients was performed between July 1, 2020, and August 30, 2020. Patients who had died were excluded from the analysis and cause of death recorded. Those who could not be contacted, were unwilling to participate, or did not complete the follow-up survey were also excluded. A link to access the online survey was sent by email following telephone contact with a neurologist to obtain consent. When contact by email was not possible (because of personal limitations or Internet access problems), the survey was administered directly to the patient or caregiver by telephone by a neurologist.

Description of online survey

The online survey consisted of three questionnaires: the 19-item questionnaire used in the first study, the Hospital Anxiety and Depression Scale (HADS), and the Pittsburgh Sleep Quality Index (PSQI). They were intended to be completed by the patient or, in the case of patients with intellectual disability, dementia, or any other condition that prevented them from answering the questions, their caregiver.

The 19 items in the questionnaire were divided into five sections: (a) effects of patient/caregiver isolation or quarantine; (b) effects of...
government-imposed lockdown on seizure frequency, AED treatment, emergency consultations, delays in epilepsy-related tests, anxiety and depression symptoms, and sleep disturbances; (c) socio-economic effects (reduced income for patient/main caregiver as a result of the lockdown); (d) perception of telephone consultations during the pandemic; and (e) symptoms compatible with COVID-19. An increase in seizure frequency was defined as an increase of 50% or more in the number of seizures reported by the patient compared to baseline (information obtained from medical record) or the occurrence of unprovoked seizures in previously seizure-free patients.

The HADS is a validated 14-item self-administered scale for detecting states of depression and anxiety. It distinguishes between emotional and somatic illness, and there is evidence that scores are not affected by the presence of bodily illness. It has an anxiety subscale (HADS-A) and a depression subscale (HADS-D), both containing seven items rated on a four-point Likert-type scale, that also provide valid measures of severity. A HADS score of 0–7 is considered to be normal; scores of 8–10 indicate borderline cases, while those of 11–21 indicate pathological cases. In this last category, a score of 11–14 indicates moderate illness while one of 14 or higher indicates severe illness.

The PSQI is a 19-item self-administered questionnaire that assesses sleep quality and disturbances over a 1-month interval. These 19 items, each rated on a four-point Likert-like scale, generate seven scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The scores are added to produce a global score. A global score of 5 or higher provides a sensitive and specific measure of poor sleep quality relative to clinical and laboratory measures.

2.3 Statistical analysis

The statistical analyses were performed in the IBM SPSS Statistics software program version 22.0. Descriptive and frequency statistical analyses were obtained. Categorical variables were reported as frequencies (percentages) and continuous variables as mean ± standard deviation or median and interquartile range, as appropriate. McNemar–Bowker’s test for paired data was used to compare questionnaire responses from the first and second studies, while the Mann-Whitney U test was used to compare self-reported depression, anxiety, and insomnia with HADS/PSQI scores. Associations between the study variables and increased seizure frequency were assessed using Pearson’s chi-square test for categorical variables or the Fisher exact test (for expected frequencies <5).

Variables with a p-value <.1 in the univariate analysis were entered into a forward stepwise multiple logistic regression model as independent variables to identify factors independently associated with an increase in seizure frequency. Odds ratios (ORs) and 95% confidence intervals (CIs) are shown in the final model. A bar chart was created to show the probability of an increase in seizure frequency according to the cumulative number of independently associated factors. P-values <.05 were considered statistically significant.

3 RESULTS

We analyzed data for 153 of the 255 epilepsy patients who participated in the initial study on the short-term effects of the COVID-19 pandemic. The details of the selection process are summarized in Figure 1. The mean age of the patients was 47.6 ± 19.3 years, and 49.7% (n = 76) were women. The most common type of epilepsy was focal epilepsy (n = 134; 87.6%), and the most common focal subtype was temporal lobe epilepsy (n = 58; 37.9%). Etiology was unknown in 40 patients (26.1%). Thirty-one patients (20.3%) had an intellectual disability, and 43 (28.1%) had dependency for activities of daily living. Thirty-two patients (20.9%) had drug-resistant epilepsy. The survey was answered by the patient in 93 cases (60.8%) and by a family member or caregiver in 69 (39.2%). The demographic and clinical characteristics are shown in Table 1.

3.1 Medium-term impact of COVID-19 lockdown and social distancing

No significant differences in seizure control were observed on comparing the short- and medium-term effects of the COVID-19 pandemic on our cohort of patients with epilepsy. In the second study, conducted in July and August 2020, 17 patients (11.1%) reported an increase in seizure frequency, 125 (81.6%) reported no change, and five (3.3%) reported a decrease. Six patients (3.6%) did not know. The short- and medium-term effects are compared in Table 2.

Demand for emergency services increased following the easing of restrictions (11.1% vs. 3.3%; p = .008). Eight patients (5.3%) visited an emergency department because of seizures in the summer and three (2%) considered doing so but did not because they were afraid of becoming infected with SARS-CoV-2. Three (2%) called the emergency phone line and were told to stay at home, and another three (2%) tried to call but could not get through because the lines were overwhelmed.

No significant differences in the number of patients reporting delays in epilepsy-related tests were observed between the first and second study (14 vs. 15). Four of the 15 patient who reported delays during the new normal also reported an increase in seizure frequency. Just four patients (2.6% vs. 2% in the first study) reported difficulties obtaining their AEDs from the pharmacy, and in all cases, the reason was that their prescription had expired.

Forty-three patients (29.3%) reported feeling depressed in the questionnaire administered in July/August; this rate was significantly higher than the rate of 19.7% observed during lockdown (p = .038). Self-reported feelings of depression were significantly associated with HADS-D score (p < .001); 17 patients (12.9%) had pathological scores on the HADS-D, while 15 (11.4%) had borderline scores. No significant changes in self-reported anxiety were
observed between the two studies (38.1% vs. 36.1%; \( p = 0.75 \)). Self-reported anxiety was also significantly associated with HADS-A score (\( p = <0.001 \)). In this case, 25 patients (19.4%) had pathological scores and 17 (13.4%) had borderline scores. No differences were observed in self-reported sleep disturbances, with 30.9% of patients reporting insomnia in the second study compared with 28.9% in the first study (\( p = .761 \)). In addition, 15 patients (9.8%) stated that they were sleeping more hours than usual. The PSQI score, which was also significantly associated with self-reported insomnia (\( p = .001 \)), indicated poor sleep quality in 66 patients (55%). Sleep efficiency was less than 85% in 48 patients (40%) (Figure 2).

The proportion of patients reporting that their main fear was COVID-19 (38.8% vs. 45.5%; \( p = .268 \)) or epilepsy (16.5% vs. 14.9%; \( p = .824 \)) remained unchanged, as did the proportion of patients reporting a reduction in family income (26.9% vs. 28.3%; \( p = .845 \)).

Several changes were observed in the factors associated with an increase in seizure frequency. In the univariate analysis, the strongest predictor of an increase in the medium term was depression, assessed using both the 19-item questionnaire (\( p = .001 \)) and the HADS-D (\( p = .002 \)). No significant associations were observed for tumor-related epilepsy or fear of epilepsy (\( p = .157 \)). Anxiety, evaluated with the 19-item questionnaire (\( p = .008 \)) and the HADS-A (\( p = .006 \)), drug-resistant epilepsy (\( p = .010 \)), reduced income (\( p = .002 \)), delayed performance of epilepsy-related tests (\( p = .034 \)), and self-reported insomnia (\( p = .004 \)), all maintained their association with an increased frequency of seizures (Table 3).

In the multivariate analysis, drug-resistant epilepsy (OR =8.2, 95% CI 2.06–32.52, \( p = .003 \)), depression (OR = 6.46, 95% CI 1.80–23.11, \( p = .004 \)), and reduced income (OR = 5.47, 95% CI 1.51–19.88, \( p = .010 \)) were all independently associated with an increased seizure frequency. The combinations of these factors also provided a cumulative probability estimate of increased frequency (Figure 3).

### 3.2 | Perceptions of telemedicine

Perceptions of telemedicine worsened significantly between the first and follow-up study (\( p = .005 \)), with a higher proportion of patients stating that they were dissatisfied (11.2% vs. 2.4%) or quite satisfied (44% vs. 40.8%) with remote visits, and a lower proportion (44.8% vs. 56.8%) stating that they were very satisfied. Their opinions regarding the usefulness of telemedicine in the near future remained unchanged (\( p = .105 \)), with 40.8% (vs. 37.4%) stating they would prefer face-to-face visits, 36.7% (vs. 41.5%) stating that they found it convenient and would like to use it, and 22.4% (vs. 21.1%) stating that they had no preference between remote and face-to-face encounters (Table 2).

### 3.3 | COVID-19 in epilepsy patients

Eight patients (5.2%) without a confirmatory diagnostic test reported symptoms compatible with mild COVID-19 in the follow-up study. There was just one patient (0.63%) with a mild infection and fever as the main symptom who had a positive RT-PCR result from a nasopharyngeal specimen. The patient did not develop pneumonia or require hospitalization and reported no changes in seizure frequency or AED use during the illness.
DISCUSSION

We have described the medium-term effects of the COVID-19 pandemic on epilepsy patients in Spain and highlighted the psychological consequences of lockdown and social distancing measures, particularly evident in the rise in depression rates and persistence of anxiety and insomnia. Approximately 10% of patients reported an increase in seizure frequency; this rate is similar to that reported during lockdown, despite the decline in infection rates and easing of social restrictions at the time of data compilation.

The sample was drawn from the "Epilepsy in time of COVID-19" cohort, a real-life cohort from an epilepsy unit at a tertiary hospital comprising a wide range of patients, including those with intellectual disability and/or dependency for activities of daily living. The percentage of patients with drug-resistant epilepsy was similar to that expected for the general epilepsy population.

The online survey was designed by a trained epileptologist, and to minimize variations, the follow-up telephone interviews were conducted by the same epileptologists who took part in the first wave of the study. In this second study, self-reported psychiatric comorbidities (depression, anxiety, and sleep disturbances) were compared with scores on the HADS and PSIQ, which have both been validated in patients with epilepsy.22,23

The main finding of this follow-up study of the medium-term effects of the COVID-19 pandemic on patients with epilepsy was a significant increase in depression rates. Almost a third of the patients reported feeling depressed, and 24.3% had borderline or pathologic scores on the HADS-D. This represents a 33% increase in self-reported depression compared with the first survey, which had already detected a rise in emerging psychiatric symptoms such as anxiety and depression during the first month of lockdown. While

| TABLE 1 | Demographic and clinical characteristics of the patients included in the study |
|-----------------------------------------------|
| Age, years, mean ± SD (range) | 47.6 ± 19.3 (17–77) |
| Sex, n (%) |  |
| Male | 77 (50.3) |
| Female | 76 (49.7) |
| Type of epilepsy, n (%) |  |
| Focal | 134 (87.6) |
| Generalized | 18 (11.8) |
| Unclassifiable | 1 (0.7) |
| Subtype of focal epilepsy, n (%) |  |
| Temporal | 58 (37.9) |
| Frontal | 34 (22.2) |
| Parietal | 5 (3.3) |
| Posterior quadrant | 6 (3.9) |
| Unknown | 32 (20.9) |
| Etiology, n (%) |  |
| Unknown | 40 (26.1) |
| Genetic* | 23 (15) |
| Vascular | 20 (13.1) |
| Tumor | 19 (12.4) |
| Perinatal anoxia | 11 (7.2) |
| Infectious disease | 9 (5.9) |
| Mesial temporal sclerosis | 7 (4.6) |
| Post-traumatic | 6 (3.9) |
| Malformations of cortical development | 5 (3.3) |
| Inflammatory/Autoimmune | 3 (2) |
| Post-anoxic encephalopathy | 3 (2) |
| Toxic/Metabolic | 2 (1.3) |
| Other | 5 (3.3) |
| Intellectual disability, n (%) | 31 (20.3) |
| Dysphagia, n (%) | 10 (6.5%) |
| mRS, n (%) |  |
| 0 | 15 (9.8) |
| 1 | 55 (35.9) |
| 2 | 43 (28.1) |
| 3 | 26 (17.1) |
| 4 | 14 (9.2) |
| 5 | 0 |
| Dependence for ADLs, n (%) | 43 (28.1) |
| Number of AEDs, n (%) |  |
| 0 | 4 (2.6) |
| 1 | 81 (52.9) |
| 2 | 43 (28.1) |
| 3 | 17 (11.1) |
| 4 | 8 (5.2) |
| Drug-resistant epilepsy, n (%) | 32 (20.9) |

(Continues)
these symptoms have also been detected in the general population, their increase has been particularly noticeable in patients with chronic illness. In Italy, 35% of epilepsy patients surveyed during the peak of the first wave of the pandemic reported depressive symptoms, while a multicountry online survey conducted around the same time found that 39.8% of patients with epilepsy had pathological HADS-D scores. In Spain, a study conducted between May and June 2020 detected feelings of sadness and depression in 35% of epilepsy patients. Pathological levels of stress and anxiety were reported in the first wave of the pandemic in up to 60% of the epilepsy population, and self-reported levels remained high (40%) during follow-up. The anxiety and depression rates detected in our study are lower than those reported elsewhere, possibly because of differences in the questionnaires used, the profile of patients surveyed (the other studies, for example, did not include patients with intellectual disability), or the timing of the studies. Our detection of a significant increase in depression rates among epilepsy patients during the new normal restrictions highlights the risk of both medium- and long-term psychological consequences.

The impact of recently acquired depression is reflected in the seizure control data. Although the increase in seizure frequency with respect to baseline remained stable during follow-up, we detected changes in the factors associated with poor control, with depression becoming the main risk factor. Psychiatric comorbidities

**TABLE 2** Comparison of short-term (Second column) and medium-term (Third column) responses to the 19-item questionnaire on the effects of the coronavirus disease 2019 pandemic on epilepsy patients. In the first column, the results of the initial analysis with the complete sample of patients are shown.

|                      | Short-term analysis\(^{15}\) (first wave) (March 16, 2020, to April 17, 2020) | Medium-term analysis (new normal) (July 1, 2020, to August 30, 2020) (n = 153) | p-value |
|----------------------|-------------------------------------------------|---------------------------------------------------------------------|---------|
| **Seizure frequency**, n (%) | | | |
| Increased | 25 (9.8) | 14 (9.1) | 17 (11.1) | .515 |
| No change | 219 (85.9) | 134 (87.3) | 125 (81.6) | |
| Decreased | 11 (4.3) | 5 (3.6) | 5 (3.26) | |
| Do not know | 0 | 0 | 6 (3.9) | |
| **Emergency consultation**\(^{a}\) n (%) | 11 (4.4) | 5 (3.3) | 17 (11.1) | .008 |
| Delays in epilepsy-related tests\(^{b}\) n (%) | 28 (11) | 14 (9.2) | 15 (9.8) | >.99 |
| Difficulties obtaining medication, n (%) | 7 (2.7) | 3 (2) | 4 (2.6) | >.99 |
| **Self-reported depression on 19-item questionnaire**, n (%) | 53 (21.2) | 29 (19.7) | 43 (29.3) | .038 |
| **Self-reported anxiety on 19-item questionnaire**, n (%) | 99 (39.6) | 53 (36.1) | 56 (38.1) | .749 |
| **Self-reported insomnia on 19-item questionnaire**, n (%) | 72 (28.7) | 47 (30.9) | 44 (28.9) | .761 |
| Fear of COVID-19, n (%) | 90 (41.3) | 55 (45.5) | 47 (38.8) | .268 |
| Fear of epilepsy, n (%) | 37 (17) | 18 (14.9) | 20 (16.5) | .824 |
| Reduction in family income, n (%) | 73 (29.1) | 41 (28.3) | 39 (26.9) | .845 |
| **Perception of telemedicine**, n (%) | | | | |
| Very satisfied | 124 (56.1) | 71 (56.8) | 56 (44.8) | .005 |
| Quite satisfied | 90 (40.7) | 51 (40.8) | 55 (44) | |
| Not satisfied | 7 (3.2) | 3 (2.4) | 14 (11.2) | |
| **Interest in using telemedicine in the future**, n (%) | | | | |
| Yes | 97 (39.6) | 61 (41.5) | 54 (36.7) | |
| Indifferent | 55 (22.4) | 31 (21.1) | 33 (22.4) | |
| No | 93 (38) | 55 (37.4) | 60 (40.8) | |

Statistically significant differences are highlighted in bold.

\(^{a}\)Includes emergency room visits and emergency telephone consultations.

\(^{b}\)Includes routine EEG, MRI, and video-EEG monitoring.
are known to have an important role in seizure control, even in non-pandemic times. A recent Spanish study identified lockdown-related emotional distress as the main risk factor for worsening seizure control in patients with epilepsy. Insomnia remained highly prevalent in our follow-up study, supporting previous findings showing worsening of sleep disturbances among epilepsy patients during the first peak of the pandemic and an association with seizure control.
The socioeconomic effects of the pandemic have also had a significant effect on psychological distress and mental health, being the socioeconomic status a known determinant of psychological distress and health outcomes among epilepsy patients. In our cohort, 27% of patients were still affected by a reduction in income several months after the easing of restrictions, and this factor was the second strongest predictor of an increase in seizure frequency.

Our findings also show a major shift in perceptions of telemedicine, with the proportion of patients reporting dissatisfaction with remote visits increasing from 2% during lockdown to around 11% in the summer. In a survey conducted during the first peak of the pandemic, 88% of Spanish epileptologists reported dealing with their patients by telephone and stated that it was difficult to handle complex issues via this channel.11 In a US study of telehealth perceptions during the pandemic,66% of epilepsy patients reported being very satisfied with teleconsultations. In our study, the proportion of patients reporting high satisfaction levels fell from 57% during lockdown to 45% in the summer. In the US study, 66% of patients were optimistic about the future role of telemedicine, compared with just 41.5% and 36.7% of patients in the first and second waves of our survey. The more favorable opinions observed in the United States may partly be due to the younger age of the patients and the fact that the survey was conducted at a time when the pandemic had not yet affected the whole country.35 The positive perceptions of telemedicine observed in our population in the first study may be biased by the fact that the survey was conducted by telephone. Nevertheless, the significant change observed over the months should lead to reflection that several adjustments need to be made to adapt telemedicine to daily practice and strengthen patients’ confidence in this valuable tool. On a more optimistic note, 67% of the patients surveyed in the United States suggested the possibility of a hybrid model combining telehealth, with telephone or video consultations, and traditional visits; this option was also spontaneously proposed by our patients and could be a good direction to pursue.

We also detected an increase in emergency consultations (from 3.3% in March/April to 11% in July/August). Some of these visits may correspond to visits that patients postponed during the early days of the pandemic because of fear of becoming infected with SARS-CoV-2 at the hospital. The proportion of patients reporting delays in testing remained similar, at around 10%, indicating that there was still a backlog to clear. Delays in the performance of epilepsy-related tests were associated with an increase in seizure frequency, and we believe that this relationship may be bidirectional, since a higher proportion of tests are ordered for patients with drug-resistant epilepsy. Nevertheless, a sooner performance of these tests could have provided important information and therefore allow treatment adjustment and a more accurate assessment in these patients.

Our study has several limitations. The pre-pandemic baseline scores for anxiety and depression were not collected in our sample, even though prior studies performed in our population area portrayed

### TABLE 3  Clinical factors associated with seizure control during and after lockdown in the first wave of the coronavirus disease 2019 pandemic

| Increased seizure frequency | First wave (March 16, 2020, to April 17, 2020) (n = 255) | New normal (July 1 to August 30) (n = 147) |
|----------------------------|------------------------------------------------------|-----------------------------------|
| No (n = 230) | Yes (n = 25) | P-value | No (n = 130) | Yes (n = 17) | p-value |
| Depression | | | | | |
| 19-item questionnaire, n (%) | 46 (20.4) | 7 (28) | 0.381 | 28 (22.6) | 11 (64.2) | 0.001 |
| HADS-D, n (%) | – | – | – | 9 (8.1) | 6 (40) | 0.002 |
| Anxiety | | | | | |
| 19-item questionnaire, n (%) | 84 (37.3) | 15 (60) | 0.028 | 40 (32.3) | 11 (64.7) | 0.008 |
| HADS-A, n (%) | – | – | – | 15 (13.9) | 7 (46.7) | 0.006 |
| Insomnia | | | | | |
| 19-item questionnaire, n (%) | 58 (25.7) | 14 (56) | 0.001 | 31 (23.8) | 10 (58.8) | 0.004 |
| PSQI, n (%) | – | – | – | 52 (51.5) | 9 (14.8) | 0.140 |
| Drug-resistant epilepsy, n (%) | 44 (19.1) | 12 (48) | 0.001 | 23 (17.7) | 8 (47.1) | 0.010 |
| Reduction in family income, n (%) | 61 (26.9) | 12 (50) | 0.018 | 28 (21.7) | 10 (58.8) | 0.002 |
| Delays in epilepsy-related tests, n (%) | 18 (7.8) | 10 (30) | <.001 | 8 (6.2) | 4 (23.5) | 0.029 |
| Tumor etiology, n (%) | 21 (9.1) | 8 (32) | 0.011 | 15 (11.5) | 4 (23.5) | 0.157 |
| Fear of epilepsy, n (%) | 28 (14.4) | 9 (39.1) | 0.002 | 14 (12.5) | 4 (26.7) | 0.140 |

Abbreviations: HADS, Hospital Anxiety and Depression Scale; PSQI, Pittsburgh Sleep Quality Index.

*The HADS and PSQI were not evaluated in the first study.*
lower rates of psychiatric pathologies before the COVID-19 pandemic.\textsuperscript{29} Besides psychological comorbidities and sleep disturbances were measured using validated tests, changes in seizure frequency were based on self-reported data. Our findings may also be affected by selection bias as just 50% of the patients from the initial study completed the follow-up survey. This low response rate was partly related to technical difficulties encountered with the online questionnaire (such as difficulties to access it or receiving it). We think that the introduction of telemedicine in our day to day will require a progressive learning process in our population, both in patients and in healthcare professionals. This study has provided new evidence on the medium-term effects of the COVID-19 pandemic on patients with epilepsy, and effects we believe are likely to endure beyond the pandemic. Further longitudinal and multicenter studies of larger international populations are needed to confirm our observations and clarify uncertainties surrounding the future consequences of the COVID-19 pandemic.

5 | CONCLUSIONS

We detected a significant increase in the proportion of epilepsy patients experiencing depressive symptoms after the first peak of the COVID-19 pandemic. The main risk factors for an increase in seizure frequency were depression, reduced income, and drug-resistant epilepsy. Anxiety and insomnia rates remained high, and perceptions of telemedicine worsened significantly. The full consequences of the COVID-19 pandemic and social distancing measures have yet to be determined in the setting of epilepsy, although as our results suggest, they are likely to be lasting and will call for adjustments to daily practice.

6 | ETHICAL PUBLICATION STATEMENT

We confirm that we have read the journal’s position on issues concerning ethical publication and that this report is consistent with these guidelines.

ACKNOWLEDGMENTS

This research did not receive a grant from funding agencies in the public, commercial, or not-for-profit sector.

CONFLICT OF INTEREST

E. Fonseca has received research funding and speakers’ fees from UCB Pharma, Esteve laboratorios, Eisai Inc, and Sanofi Genzyme. L. Abaira has received research funding and speakers’ fees from UCB Pharma, BIAL Pharmaceutical, EISAI Inc., Sanofi Genzyme, and Esteve laboratorios. E. Santamarina has received research funding and speakers’ fees from UCB Pharma, BIAL Pharmaceutical, EISAI Inc. Arvelle, and Esteve laboratorios. I. Seijo-Raposo has received research funding from UCB Pharma, Neuraxpharm, and GW pharmaceuticals. M. Toledo has received research funding and speakers’ fees from UCB Pharma, BIAL Pharmaceutical, EISAI Inc., Sanofi, Arvelle, and Esteve laboratorios. S. Lallana, M. Quintana, JL. Restrepo and J. Álvarez-Sabin have no conflicts of interest to declare.

DATA AVAILABILITY STATEMENT

After publication, anonymized data supporting the findings of this study will be available from the corresponding author upon reasonable request from any qualified investigator.

ORCID

Sofía Lallana https://orcid.org/0000-0002-5999-9889
Elena Fonseca https://orcid.org/0000-0002-3895-1237
Juan Luis Restrepo https://orcid.org/0000-0002-6332-6126
Manuel Quintana https://orcid.org/0000-0003-0288-9088
Iván Seijo-Raposo https://orcid.org/0000-0002-8171-443X
Laura Abaira https://orcid.org/0000-0002-5119-7929
Estevo Santamaria https://orcid.org/0000-0003-1915-0335
José Álvarez-Sabin https://orcid.org/0000-0002-8054-9209
Manuel Toledo https://orcid.org/0000-0003-1550-3316

REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
2. WHO COVID-19 Dashboard. https://covid19.who.int/. Accessed December 1, 2020.
3. Real Decreto-ley 21/2020, de 9 de junio, de medidas urgentes de prevención, contención y coordinación para hacer frente a la crisis sanitaria ocasionada por el COVID-19. https://www.boe.es/diario_boe/txt.php?id=BOE-A-2020-5895. Accessed December 1, 2020.
4. Situación y evolución de la pandemia de COVID-19 en España. https://cneucovid.isciii.es/. Accessed December 1, 2020.
5. Walker LE, Heaton HA, Monroe RJ, et al. Impact of the SARS-CoV-2 Pandemic on Emergency Department Presentations in an Integrated Health System. Mayo Clin Proc. 2020;95(11):2395-2407.
6. Wright A, Salazar A, Mirica M, Volk LA, Schiff GD. The invisible epidemic: neglected chronic disease management during COVID-19. J Gen Intern Med. 2020;35(9):2816-2817.
7. Chudasama YV, Gilles CL, Zaccardi F, et al. Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals. Diabetes Metab Syndr. 2020;14(5):965-967.
8. Sirina Keesara MD, Andrea Jonas MD, Kevin SM. Covid-19 and Health Care’s Digital Revolution. N Engl J Med. Published online. 2020;382(23):1-2.
9. French JA, Brodie MJ, Caraballo R, et al. Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology. 2020;94(23):1032-1037.
10. Adan GH, Mitchell JW, Marston T. Epilepsy care in the COVID-19 era. Clin Med J R Coll Physicians London. 2020;20(4):E104-E106.
11. Conde-Blanco E, Centeno M, Tio E, et al. Emergency implementation of telemedicine for epilepsy in Spain: results of a survey during SARS-CoV-2 pandemic. Epilepsy Behav. 2020;111:107211.
12. Nakamoto M, Carrazana E, Vierek J, Liow K. Epilepsy in the time of COVID-19. Acta Neurol Scand. 2021;143(3):333-335.
13. Conde Blanco E, Manzanares I, Centeno M, et al. Epilepsy and lockdown: a survey of patients normally attending a Spanish centre. Acta Neurol Scand. Published online. 2020;0-1. https://doi.org/10.1111/ane.13354.
14. Cabezudo-García P, Ciano-Petersen NL, Mena-Vázquez N, Pons-Pons G, Castro-Sánchez MV, Serrano-Castro PJ. Incidence and case fatality rate of COVID-19 in patients with active epilepsy. Neurology. 2020;95(10):e1417-e1425.
15. Fonseca E, Quintana M, Lallana S, et al. Epilepsy in time of COVID-19: a survey-based study. Acta Neurol Scand. 2020;142(6):545-554.
16. Real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gestión de la situación de la crisis sanitaria ocasionada por el COVID-19. https://www.boe.es/buscar/doc.php?id=BOE-A-2020-3692. Accessed December 1, 2020.
17. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE Official Report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482.
18. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-521.
19. Zigmond AS, Snalht RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-370.
20. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
21. Kong ST, Ho CS, Ho PC, Lim SH. Prevalence of drug resistant epilepsy in adults with epilepsy attending a neurology clinic of a tertiary referral hospital in Singapore. Epilepsia Res. 2014;108(7):1253-1262.
22. Wiglusz MS, Landowski J, Michaelak L, Cubala WJ. Validation of the Hospital Anxiety and Depression Scale in patients with epilepsy. Epilepsy Behav. 2016;58:97-101.
23. Maća A. NDT-136868-the-sleep-disturbances-among-patients-with-epilepsy. Published online. 2017:1797-1803.
24. Salari N, Hosseini-Far A, Jalali R, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Global Health. 2020;16(1):1-11.
25. Assenza G, Lanzone J, Brigo F, et al. Epilepsy care in the time of COVID-19 pandemic in Italy: risk factors for seizure worsening. Front Neurol. 2020;11:11.
26. Van Hees S, Siewe Fodjo JN, Wijtvliet V, et al. Access to healthcare and prevalence of anxiety and depression in persons with epilepsy during the COVID-19 pandemic: a multicountry online survey. Epilepsy Behav. 2020;112:107350.
27. Sanchez-Larsen A, Gonzalez-Villar E, Diaz-Maroto I, et al. Influence of the COVID-19 outbreak in people with epilepsy: analysis of a Spanish population (EPICOVID registry). Epilepsy Behav. 2020;112:107396.
28. Dias R, Bateman LM, Farias ST, et al. Depression in epilepsy is associated with lack of seizure control. Epilepsy Behav. 2010;19(3):445-447.
29. Campos-Fernández D, Fonseca E, Oliva-Gadea M, et al. The mediating role of epileptic seizures, irritability, and depression on quality of life in people with epilepsy. Epilepsy Behav. 2020;113:107511.
30. Alkhotani A, Siddiqui M, Almuntashri F, Baothman R. The effect of COVID-19 pandemic on seizure control and self-reported stress on patient with epilepsy. Epilepsy Behav. 2020;112:107323.
31. dos Santos CF, Picó-Pérez M, Morgado P. COVID-19 and Mental Health—What Do We Know So Far? Front Psychiatry. 2020;11:1-6.
32. Elliott JO, Charyton C, Lu B, Moore JL. Serious psychological distress and health outcomes for persons with epilepsy in poverty. Seizure. 2009;18(5):332-338.
33. Yang Y, Yang M, Shi Q, Wang T, Jiang M. Risk factors for depression in patients with epilepsy: a meta-analysis. Epilepsy Behav. 2020;106:107030.
34. Casares M, Wombles C, Skinner HJ, Westerveld M, Greesh ED. Telehealth perceptions in patients with epilepsy and providers during the COVID-19 pandemic. Epilepsy Behav. 2020;112:107394.
35. COVID 19 United States Cases by County. https://coronavirus.jhu.edu/us-map. Accessed December 15, 2020.

How to cite this article: Lallana S, Fonseca E, Restrepo JL, et al. Medium-term effects of COVID-19 pandemic on epilepsy: A follow-up study. Acta Neurol Scand. 2021;144:99–108. https://doi.org/10.1111/ane.13439